A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
Completed · Phase 3 · NCT05134649
Conditions: Platysma Prominence
At a glance
- Research payments reported, 2025
- $4,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 292
About the trial
- Sponsor
- AbbVie
- Tested
- OnabotulinumtoxinA (drug)
- Dates
- Started 2021-11-16; completion 2023-08-18
- Results posted
- Yes
This is a Phase 3, open-label extension study to evaluate the long-term safety of repeat BOTOX treatments in adult participants with Platysma Prominence. Participants who completed the lead-in Phase 3 Study M21-309 and met eligibility requirements could enroll in this open-label extension study. Planned study enrollment was approximately 270 participants. Participants who met treatment criteria could receive up to 3 administrations of BOTOX. Day 1 (study entry) was the same day as Day 120/study exit visit of the lead-in Phase 3 study. The first administration of study drug could occur at the Day 1 visit, and the last administration of study drug could occur at the Day 180 visit (60 days p…
From ClinicalTrials.gov, last updated 2024-12-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $4,000 in research payments for this study in 2025 (1 payments).
Products named: Botox
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Skindc PLLC $4,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.